Serum Proteomics Reveals Survival-Associated Biomarkers in Pancreatic Cancer Patients Treated with Chemoimmunotherapy
Description
We conducted proteome analysis of serum samples derived from a multi-center phase 2 clinical trial for Stage IV PDAC patients as detailed in the work of Padron et al (Padron et al, Nature Medicine 2022). We analysed two treatment arms, namely Nivolumab (PD-1 inhibitor) / chemotherapy as well as Sotigalimab (CD40 agonistic antibody) / chemotherapy. Samples were longitudinally collected, with pretreatment sample collection as well as up to four subsequent collections. The number of patients analysed was 31 (Nivolumab arm) and 29 (Sotigalimab). In total we analysed 211 samples and applied a semi-automated sample preparation workflow with depletion and an optimised data-independent acquisition LC-MS measurements adapted from Bruderer et al (Bruderer et al., MCP, 2017). The processed proteome data is provided here. For details on acquisition methods and data processing, please refer to the methods section of the corresponding manuscript (Tognetti et al., iScience, 2025).